07288251 is referenced by 34 patents and cites 134 patents.

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

Title
Antibodies to CD40
Application Number
10/292088
Publication Number
7288251 (B2)
Application Date
November 8, 2002
Publication Date
October 30, 2007
Inventor
Xiao Feng
Union City
CA, US
Xiao Chi Jia
San Mateo
CA, US
Jose Corvalan
Foster City
CA, US
Ronald P Gladue
Stonington
CT, US
Vahe Bedian
East Lyme
CT, US
Agent
Ropes & Gray
Z Ying Li
Jane T Gunnison
Assignee
Pfizer
NY, US
Abgenix
CA, US
IPC
C07K 16/28
A61K 39/395
View Original Source